Evidence map›Paper›PMID 36970141›Full record

ArticleRSC medicinal chemistry2023

Design, synthesis and

Jay Prakash Soni, Shrilekha Chilvery, Anamika Sharma, G Nikitha Reddy, Chandraiah Godugu, Nagula Shankaraiah

Open access · greenAbstract read
In one paragraph

Article in RSC medicinal chemistry, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 1 institution in 1 country.

Jay Prakash SoniDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500036 India shanakr@niperhyd.ac.in shankarnbs@gmail.com.ORCID https://orcid.org/0000-0001-7268-3697
Shrilekha ChilveryDepartment of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500036 India chandra.niperhyd@gov.in.
Anamika SharmaDepartment of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500036 India chandra.niperhyd@gov.in.
G Nikitha ReddyDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500036 India shanakr@niperhyd.ac.in shankarnbs@gmail.com.
Chandraiah GoduguDepartment of Regulatory Toxicology, National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500036 India chandra.niperhyd@gov.in.
Nagula ShankaraiahDepartment of Medicinal Chemistry, National Institute of Pharmaceutical Education and Research (NIPER) Balanagar Hyderabad 500036 India shanakr@niperhyd.ac.in shankarnbs@gmail.com.ORCID https://orcid.org/0000-0002-8733-9431
National Institute of Pharmaceutical Education and Research (NIPER) - Ahmedabad · IN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In the pursuit of potential and effective chemotherapeutic agents, a series of 2-((3-(indol-3-yl)-pyrazol-5-yl)imino)thiazolidin-4-ones was designed and synthesized, conjoining salient pharmacophoric properties for directing prominent cytotoxicity. The

Identifiers

PMID36970141
PMCPMC10033828
OpenAlexW4317932136

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.